none10noThe project was granted by Ministero della Salute, Bando Ricerca Finalizzata 2010.Purpose: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspected recurrent or residual disease. Methods: Adult lymphoma patients presenting with positive or equivocal F-18-FDG PET/CT at end-treatment or follow-up were prospectively addressed to an additional F-18-FLT-PET/CT. SUV max and tumour-to-background ratios (TBRs) were recorded for the most avid lesion. Biopsy or, when not available, clinical or imaging assessment were employed as standard of reference. Results: Overall 52 patients were recruited. Histology was available in 20/52 patients (38%), proliferation-index (Ki-67) in 14/20. Disease was ...
Aim: Despite recent local introduction of evidence‐based guidelines recommending PET‐CT (low dose un...
PURPOSE: We present findings concerning (18)F-fluorodeoxyglucose (FDG) positron emission tomography...
Conclusion This thesis evaluated the role of [18F]FDG PET as a biomarker in aggressive lymphoma by b...
Purpose: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspec...
BACKGROUND: The aim of the study was to evaluate the usefulness of 18F-FDG-PET in patients with g...
Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT...
Positron emission tomography (PET) using (18)F-fluorodeoxyglucose ((18)F-FDG) is the best noninvasiv...
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to ...
International audiencePURPOSE: The aim of this study was to assess the usefulness of positron emissi...
BACKGROUND: The role of [\ub9\u2078F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) i...
This study aimed to systematically review the value of end-of-treatment 18F-fluoro-2-deoxy-D-glucose...
Lymphomas are a heterogeneous group of malignancies that have a distinct biological behavior accordi...
Radiotherapy (RT) can be curative in patients with localized follicular lymphoma (FL), with historic...
Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/...
BACKGROUND. The authors undertook a prospective evaluation of the clinical value of 2-fluoro [18-1-2...
Aim: Despite recent local introduction of evidence‐based guidelines recommending PET‐CT (low dose un...
PURPOSE: We present findings concerning (18)F-fluorodeoxyglucose (FDG) positron emission tomography...
Conclusion This thesis evaluated the role of [18F]FDG PET as a biomarker in aggressive lymphoma by b...
Purpose: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspec...
BACKGROUND: The aim of the study was to evaluate the usefulness of 18F-FDG-PET in patients with g...
Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT...
Positron emission tomography (PET) using (18)F-fluorodeoxyglucose ((18)F-FDG) is the best noninvasiv...
PET/CT using (18)F-FDG is an essential part of the management of patients with lymphoma. Efforts to ...
International audiencePURPOSE: The aim of this study was to assess the usefulness of positron emissi...
BACKGROUND: The role of [\ub9\u2078F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) i...
This study aimed to systematically review the value of end-of-treatment 18F-fluoro-2-deoxy-D-glucose...
Lymphomas are a heterogeneous group of malignancies that have a distinct biological behavior accordi...
Radiotherapy (RT) can be curative in patients with localized follicular lymphoma (FL), with historic...
Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/...
BACKGROUND. The authors undertook a prospective evaluation of the clinical value of 2-fluoro [18-1-2...
Aim: Despite recent local introduction of evidence‐based guidelines recommending PET‐CT (low dose un...
PURPOSE: We present findings concerning (18)F-fluorodeoxyglucose (FDG) positron emission tomography...
Conclusion This thesis evaluated the role of [18F]FDG PET as a biomarker in aggressive lymphoma by b...